334 related articles for article (PubMed ID: 21468024)
1. Growth hormone pharmacogenetics: the interactive effect of a microsatellite in the IGF1 promoter region with the GHR-exon 3 and -202 A/C IGFBP3 variants on treatment outcomes of children with severe GH deficiency.
Costalonga EF; Antonini SR; Guerra G; Coletta RR; Franca MM; Braz AF; Mendonca BB; Arnhold IJ; Jorge AA
Pharmacogenomics J; 2012 Oct; 12(5):439-45. PubMed ID: 21468024
[TBL] [Abstract][Full Text] [Related]
2. The interactive effect of GHR-exon 3 and -202 A/C IGFBP3 polymorphisms on rhGH responsiveness and treatment outcomes in patients with Turner syndrome.
Braz AF; Costalonga EF; Montenegro LR; Trarbach EB; Antonini SR; Malaquias AC; Ramos ES; Mendonca BB; Arnhold IJ; Jorge AA
J Clin Endocrinol Metab; 2012 Apr; 97(4):E671-7. PubMed ID: 22278433
[TBL] [Abstract][Full Text] [Related]
3. Association of the (CA)n repeat polymorphism of insulin-like growth factor-I and -202 A/C IGF-binding protein-3 promoter polymorphism with adult height in patients with severe growth hormone deficiency.
Miletta MC; Scheidegger UA; Giordano M; Bozzola M; Pagani S; Bona G; Dattani M; Hindmarsh PC; Petkovic V; Oser-Meier M; Flück CE; Mullis PE
Clin Endocrinol (Oxf); 2012 May; 76(5):683-90. PubMed ID: 22026507
[TBL] [Abstract][Full Text] [Related]
4. Genetic predictors of long-term response to growth hormone (GH) therapy in children with GH deficiency and Turner syndrome: the influence of a SOCS2 polymorphism.
Braz AF; Costalonga EF; Trarbach EB; Scalco RC; Malaquias AC; Guerra-Junior G; Antonini SR; Mendonca BB; Arnhold IJ; Jorge AA
J Clin Endocrinol Metab; 2014 Sep; 99(9):E1808-13. PubMed ID: 24905066
[TBL] [Abstract][Full Text] [Related]
5. The -202 A allele of insulin-like growth factor binding protein-3 (IGFBP3) promoter polymorphism is associated with higher IGFBP-3 serum levels and better growth response to growth hormone treatment in patients with severe growth hormone deficiency.
Costalonga EF; Antonini SR; Guerra-Junior G; Mendonca BB; Arnhold IJ; Jorge AA
J Clin Endocrinol Metab; 2009 Feb; 94(2):588-95. PubMed ID: 18984657
[TBL] [Abstract][Full Text] [Related]
6. Additive effect of GHRd3 and COLIA1 polymorphisms on the GH-substitution dose in GH-deficient adults.
Hartleb S; Plöckinger U; Stalla GK; Tuschy U; Weber MM; Pfützner A; Kann PH; ;
Pharmacogenomics; 2011 Dec; 12(12):1653-61. PubMed ID: 22026923
[TBL] [Abstract][Full Text] [Related]
7. Growth Hormone (GH) receptor C.1319 G>T polymorphism, but not exon 3 retention or deletion is associated with better first-year growth response to GH therapy in patients with GH deficiency.
Wan L; Chen WC; Tsai Y; Kao YT; Hsieh YY; Lee CC; Tsai CH; Chen CP; Tsai FJ
Pediatr Res; 2007 Dec; 62(6):735-40. PubMed ID: 17957148
[TBL] [Abstract][Full Text] [Related]
8. The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children.
Binder G; Baur F; Schweizer R; Ranke MB
J Clin Endocrinol Metab; 2006 Feb; 91(2):659-64. PubMed ID: 16291706
[TBL] [Abstract][Full Text] [Related]
9. IGF-I and IGF binding protein-3 levels during initial GH dosage step-up are indicators of GH sensitivity in GH-deficient children and short children born small for gestational age.
Ranke MB; Traunecker R; Martin DD; Schweizer R; Schwarze CP; Wollmann HA; Binder G
Horm Res; 2005; 64(2):68-76. PubMed ID: 16113581
[TBL] [Abstract][Full Text] [Related]
10. Association of the exon 3 deleted/full-length GHR polymorphism with recombinant growth hormone dose in growth hormone-deficient adults.
Meyer S; Schaefer S; Stolk L; Arp P; Uitterlinden AG; Plöckinger U; Stalla GK; Tuschy U; Weber MM; Weise A; Pfützner A; Kann PH
Pharmacogenomics; 2009 Oct; 10(10):1599-608. PubMed ID: 19842933
[TBL] [Abstract][Full Text] [Related]
11. GH responsiveness in a large multinational cohort of SGA children with short stature (NESTEGG) is related to the exon 3 GHR polymorphism.
Tauber M; Ester W; Auriol F; Molinas C; Fauvel J; Caliebe J; Nugent T; Fryklund L; Ranke MB; Savage MO; Clark AJ; Johnston LB; Hokken-Koelega AC;
Clin Endocrinol (Oxf); 2007 Sep; 67(3):457-61. PubMed ID: 17555507
[TBL] [Abstract][Full Text] [Related]
12. Impact of IGF(CA)19 gene polymorphism on the metabolic response to GH therapy in adult GH-deficient patients.
Giavoli C; Profka E; Sala E; Filopanti M; Barbieri AM; Bergamaschi S; Ferrante E; Arosio M; Ambrosi B; Lania AG; Spada A; Beck-Peccoz P
Eur J Endocrinol; 2014 Feb; 170(2):273-81. PubMed ID: 24217936
[TBL] [Abstract][Full Text] [Related]
13. Growth hormone (GH) pharmacogenetics: influence of GH receptor exon 3 retention or deletion on first-year growth response and final height in patients with severe GH deficiency.
Jorge AA; Marchisotti FG; Montenegro LR; Carvalho LR; Mendonca BB; Arnhold IJ
J Clin Endocrinol Metab; 2006 Mar; 91(3):1076-80. PubMed ID: 16291702
[TBL] [Abstract][Full Text] [Related]
14. The exon 3-deleted/full-length growth hormone receptor polymorphism and response to growth hormone therapy in growth hormone deficiency and Turner syndrome: a multicenter study.
Baş F; Darendeliler F; Aycan Z; Çetinkaya E; Berberoğlu M; Sıklar Z; Öcal G; Timirci Ö; Çetinkaya S; Darcan Ş; Gökşen Şimşek D; Bideci A; Cinaz P; Böber E; Demir K; Bereket A; Turan S; Atabek ME; Tütüncüler F; Isbir T; Bozkurt N; Kabataş Eryılmaz S; Uzunhan O; Küçükemre Aydın B; Bundak R
Horm Res Paediatr; 2012; 77(2):85-93. PubMed ID: 22456308
[TBL] [Abstract][Full Text] [Related]
15. Impact of the exon 3-deleted growth hormone (GH) receptor polymorphism on baseline height and the growth response to recombinant human GH therapy in GH-deficient (GHD) and non-GHD children with short stature: a systematic review and meta-analysis.
Wassenaar MJ; Dekkers OM; Pereira AM; Wit JM; Smit JW; Biermasz NR; Romijn JA
J Clin Endocrinol Metab; 2009 Oct; 94(10):3721-30. PubMed ID: 19584188
[TBL] [Abstract][Full Text] [Related]
16. Association of serum components of the GH-IGFs-IGFBPs system with GHR-exon 3 polymorphism in normal and idiopathic short stature children.
Ballerini MG; Domené HM; Scaglia P; Martínez A; Keselman A; Jasper HG; Ropelato MG
Growth Horm IGF Res; 2013 Dec; 23(6):229-36. PubMed ID: 23999134
[TBL] [Abstract][Full Text] [Related]
17. Role of IGF1-(CA)19 promoter microsatellite in the clinical presentation of acromegaly.
Sala E; Filopanti M; Ferrante E; Barbieri AM; Malchiodi E; Verrua E; Giavoli C; Lania AG; Arosio M; Beck-Peccoz P; Spada A; Mantovani G
Eur J Clin Invest; 2014 Dec; 44(12):1222-9. PubMed ID: 25370837
[TBL] [Abstract][Full Text] [Related]
18. Genetic and epigenetic variability in the gene for IGFBP-3 (IGFBP3): correlation with serum IGFBP-3 levels and growth in short children born small for gestational age.
van der Kaay DC; Hendriks AE; Ester WA; Leunissen RW; Willemsen RH; de Kort SW; Paquette JR; Hokken-Koelega AC; Deal CL
Growth Horm IGF Res; 2009 Jun; 19(3):198-205. PubMed ID: 18929499
[TBL] [Abstract][Full Text] [Related]
19. Different relationships between the first 2 years on growth hormone treatment and the d3-growth hormone receptor polymorphism in short small-for-gestational-age (SGA) children.
Dörr HG; Bettendorf M; Hauffa BP; Mehls O; Rohrer T; Stahnke N; Pfäffle R; Ranke MB;
Clin Endocrinol (Oxf); 2011 Nov; 75(5):656-60. PubMed ID: 21623854
[TBL] [Abstract][Full Text] [Related]
20. Growth hormone receptor exon 3 isoforms and their implication in growth disorders and treatment.
Jorge AA; Arnhold IJ
Horm Res; 2009 Apr; 71 Suppl 2():55-63. PubMed ID: 19407498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]